Laurent Keiser

📢 MedTech Europe unveils Facts & Figures 2025, a snapshot of innovation and impact in Europe   Europe’s medical technology sector 🔬 continues to grow as a powerhouse of innovation and economic strength, according to Facts & Figures 2025, published today by MedTech Europe.   The report reveals a sector that is both highly innovative and deeply rooted in Europe’s economy and health systems: ✅  930,000+ people employed: more than the population of Amsterdam, with each role generating €183,000 in value. ✅  Europe is home to 38,000+ companies, 90% of them SMEs, many with fewer than 50 employees, yet driving innovation across borders. ✅  15,700+ patents filed in 2024, equal to one every 30 minutes, confirming medtech’s place among the leading fields at the European Patent Office. MedTech Europe’s Facts & Figures 2025 is the most comprehensive resource on Europe’s medical technology sector. Designed as a practical tool, the report draws on trusted sources, including Eurostat, the European Patent Office, and market analyses, to provide an authoritative overview for policymakers, healthcare professionals, and industry stakeholders.   The Facts & Figures 2025 is available here➡️https://bit.ly/3VrLpPV

199

7 commentaires

Nicolas Ploquin succeeds Markus Boehringer as CEO of Acteon Group   Nicolas's mission will be to continue Acteon's successful development over the past years to foster its position as one of the leading dental companies in its key market segments (prophylaxis, imaging, consumables). He will continue to execute the commercial acceleration and operational improvement pathway for the group.   He will continue focusing on Acteon's recognized excellence in R&D, which has just launched “OPUS”, a combined Ultrasonics & Air Polisher, X-MIND OPTIMA 3D, a new CBCT boosted by AI, and C20, an ultra-ergonomic HD intra-oral camera. All three products perfectly designed to improve diagnostic and patient care in the dental office.   Markus Boehringer will stay with Acteon Group as Vice-Chairman of the Supervisory Board. He will continue to provide his strategic expertise and support, particularly in guiding the further development of Acteon’s anesthetics business, as well as in driving R&D and product innovation.   Nicolas Ploquin, CEO of Acteon: "I am very happy to be joining Acteon and to take on the responsibility of growing such an iconic company in the dental sector, recognized for the quality of its products and its capacity for innovation. I look forward to accelerating the launch of new solutions supporting dental practitioners in delivering better patient care and advancing oral health for tens of millions of people worldwide. I’m also thrilled to have Markus on board and to capitalize on his extensive experience".   Markus Boehringer, Vice-Charmain of Acteon Supervisory Board: “After leading the launch of several outstanding products and the successful joint acquisition of Inibsa, I am delighted to hand over the leadership of Acteon to Nicolas as my successor as CEO. I now look forward to being the Vice-Chairman of the Group, where my focus will be on supporting the company's further growth and development and serving as a strategic resource for Nicolas and his team. DENTRESSANGLE

587

115 commentaires

“If we want to secure European healthcare provision for the long term, we need to maintain key pharmaceutical capacities in Europe – and that requires reliable logistics hubs.” EUROAPI is a leading global provider of active pharmaceutical ingredients (APIs) and continues to manufacture in Europe. At its Frankfurt site in Industriepark Höchst, the company produces 25 APIs used in everyday medicines – from tablets to injections. The products are distributed worldwide, but their delivery process is highly complex. Every step is precisely scheduled, yet changes can occur at short notice, requiring a high degree of flexibility. “We need reliable partners to ensure that our products reach their destination on time and with quality assured,” says Reinhold Ziegler, Head of Supply Chain at EUROAPI Germany. The Frankfurt CargoHub at Frankfurt Airport (FRA) is one such partner, providing EUROAPI with  a wide range of competitive advantages for both imports and exports.  Curious to know more? Check out the full story: https://lnkd.in/e88AmN_s #CreatingTheFutureOfCargoTogether #cargo #pharma #euroapi #fraport #frankfurtairport #ConnetingTheWorldWithTomorrow

119

Inflexion is pleased to announce it has entered an agreement for the sale of its investment in European LifeCare Group, the largest provider of #vaccinations in Europe, to a European private equity group. Inflexion supported ELCG’s transformation from a travel vaccination provider into a leading preventative #healthcare platform with footprint across Northern Europe. During Inflexion’s investment, ELCG successfully expanded into the Benelux and Swedish markets, strengthened its leadership team and delivered strong organic growth through its direct-to-consumer marketing. With Inflexion’s support, ELCG achieved four acquisitions, nearly tripled its revenue growth, increased the number of clinics by 65% and the total number of vaccinations delivered rose fourteenfold to over 3 million annually. ➡️ Read more: https://lnkd.in/ePam4wqB #BackingAmbition #AcceleratingGrowth

153

2 commentaires

AI is no longer a promise for healthcare — it’s happening now. From the France Healthcare Innovation Summit to real-world impact, the transformation is underway. 🔹 Personalized treatment plans powered by AI 🔹 Faster, smarter care in underserved areas 🔹 Patients empowered with real-time insights 🔹 Specialized AI models that reduce costs and boost outcomes 🔗Read more on this article by Lucas Najun Dubos MD MSc MBA: https://lnkd.in/dDgEswZ9 #AIinHealthcare

146

2 commentaires

One2Treat, a Louvain-La-Neuve, Belgium-based tech company focused on integrating the patient voice into clinical development, has secured an undisclosed amount in a Seed extension funding round. One2Treat, led by CEO Sébastien Coppe, has secured undisclosed funding to expand its operations and further develop its platform. Sébastien Coppe, PhD | Marc Buyse | Pascal Piedbois 🔗 Read full article link in comment #One2Treat #PatientCentric #ClinicalTrials #HealthTech #BiopharmaInnovation #MedicalResearch #RegulatoryScience #DigitalHealth #eustartups #news

88

8 commentaires